Nasopharyngeal carcinoma

This trial tests an experimental drug called FLX475, given alone or with the immunotherapy pembrolizumab, in people with advanced cancers that have not responded to standard treatments. The study aims to find the safest dose and to see whether the combination can shrink tumors. P…

This phase 1 trial tests an experimental drug called MRG003 in people with advanced solid tumors, including colorectal cancer, head and neck squamous cell carcinoma, and nasopharyngeal carcinoma. The study aims to find a safe dose and to see whether the drug can shrink tumors. Pa…

This phase I study is testing a subcutaneous (under the skin) injection of toripalimab, an immunotherapy drug, for people with advanced nasopharyngeal carcinoma. The trial compares the new injection to the standard intravenous (IV) version, looking at safety, tolerability, and ho…

This study tested whether adding an extra chemotherapy drug (capecitabine) after standard treatment helps people with advanced nasopharyngeal cancer that is likely to spread. 294 patients received either standard chemoradiotherapy alone or standard treatment plus capecitabine. Th…

This phase 2 trial tested a drug called KL-A167 in 153 adults with recurrent or metastatic nasopharyngeal carcinoma (a type of throat cancer). Participants received the drug by IV every two weeks. The main goal was to see how many patients' tumors shrank or disappeared. The study…

This phase 3 trial tested whether giving only radiation therapy works as well as radiation plus chemotherapy for people with intermediate-risk nasopharyngeal cancer. The study enrolled 338 participants and used modern intensity-modulated radiation therapy (IMRT). The goal was to …

This study tested a new drug combination (TQB2618 plus penpulimab) in 47 people with advanced nasopharyngeal carcinoma that had come back or spread. Some participants had already tried standard treatments, while others were new to therapy. The goal was to see if the combination w…

This early-phase trial tested a new type of cell therapy for people with advanced nasopharyngeal cancer linked to the Epstein-Barr virus. Nine patients received specially engineered immune cells (TCR-T cells) designed to recognize and attack the virus-infected cancer cells. The m…

This phase II trial tested whether adding the immunotherapy drug nivolumab (Opdivo) to standard chemoradiation helps treat stage II-IVB nasopharyngeal carcinoma, a type of throat cancer. Forty patients received nivolumab infusions every two weeks alongside cisplatin chemotherapy …

This phase 2 trial tested whether adding the immunotherapy drug pembrolizumab after standard chemoradiotherapy could help people with advanced nasopharyngeal carcinoma. Fifty-three patients received either pembrolizumab or a placebo every three weeks for up to a year. The main go…

This study tested a new combination of chemotherapy drugs (nab-paclitaxel, cisplatin, and fluorouracil) given before standard chemoradiation in 60 people with advanced nasopharyngeal cancer. The goal was to see if this approach could shrink tumors and improve survival. The trial …

This early-phase study tested a combination of two immunotherapy drugs, BGB-A445 and tislelizumab, in 204 people with advanced solid tumors including lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. The trial is now comp…

This phase 3 trial tested whether adding the immunotherapy drug toripalimab to standard chemotherapy helps people with recurrent or metastatic nasopharyngeal cancer live longer without their disease getting worse. About 289 adults with advanced cancer that could not be treated wi…

This study tested a new way to find small cancer spots in neck lymph nodes of people with nasopharyngeal cancer. Researchers combined MRI scans with a special ultrasound that uses a contrast agent. They aimed to create a better rule for spotting these tiny metastases. 348 patient…

This trial tests whether a mouthwash containing lithium can prevent or reduce oral mucositis (painful mouth sores) and dysgeusia (taste changes) in people receiving radiation for head and neck tumors. Participants will rinse with either a lithium mouthwash or a placebo during the…

This study tested two types of radiation therapy for nasopharyngeal cancer (a cancer in the upper throat). One group received standard photon radiation plus carbon ion therapy, and the other received proton radiation plus carbon ion therapy. The main goal was to see which approac…

This phase 3 trial tested whether ulinastatin, a drug that blocks certain enzymes, can reduce severe mouth sores caused by chemoradiotherapy in 179 patients with advanced nasopharyngeal cancer. Patients received either standard care or ulinastatin alongside their cancer treatment…

This study looks back at tissue samples from patients with nasopharyngeal carcinoma who took part in an earlier treatment trial. Researchers are using advanced genetic testing and protein analysis to look for markers linked to how long patients survive. The goal is to better unde…

This study looked at whether three blood proteins (pre-albumin, retinol binding protein, and transferrin) can help detect early malnutrition in people with advanced nasopharyngeal cancer undergoing chemoradiotherapy. Researchers tracked 60 patients to see if these proteins change…

This completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…

This completed study looked at 7 patients with advanced nasopharyngeal carcinoma (stage N3) to see if doing neck dissection (surgery to remove lymph nodes) before radiation therapy could improve outcomes. The goal was to understand if this approach reduces the chance of cancer co…